Furthermore, in AD preclinical models, troxerutin inhibited AChE activity and stimulated the PI3K/Akt pathway, demonstrating its ability to target the key molecular mechanisms underlying the cognitive dysfunction in diabetes [278]. This evidence concerns the gene ACHE and diabetes mellitus.